Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL-208 in Mild Cognitive Impairment Following CABG
NCT00404014Phase 2Completed
- Sponsor
- Allon Therapeutics Inc.
- Start
- Aug 2006
- Primary completion
- Jun 2008
- Modality
- Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of davunetide in Mild Cognitive Impairment (MCI), sponsored by Allon Therapeutics Inc.. Started Aug 2006; status: completed.
02
Drugs
davunetide
03
Conditions
Mild Cognitive Impairment (MCI)
Beyond the preview
Go deeper on NCT00404014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00404014.